Institutional members access full text with Ovid®

Share this article on:

Intestinal microbiota in inflammation and insulin resistance: relevance to humans

De Bandt, Jean-Pascala,c; Waligora-Dupriet, Anne-Judithb; Butel, Marie-Joséb

Current Opinion in Clinical Nutrition & Metabolic Care: July 2011 - Volume 14 - Issue 4 - p 334–340
doi: 10.1097/MCO.0b013e328347924a
Genes and cell metabolism: Edited by Nada Abumrad

Purpose of review The gut microbiota is a very complex ecosystem which interacts extensively with the host, influencing multiple metabolic and physiological functions. Several diseases have been shown to be associated with specific alterations in gut microbiota. It is more and more underscored as playing a major role in the development of insulin resistance and inflammation associated with excess weight gain.

Recent findings Recent studies in obese patients have shown perturbations in gut microbiota with a weight gain-associated increase in the Firmicutes/Bacteroidetes ratio ameliorated by various attempts at inducing weight loss.

Summary Intestinal microbiota may contribute to the development of inflammation and insulin resistance by two main mechanisms. First, gut microbiota might facilitate energy harvest from the gut leading via perturbation in energy homeostasis to fat deposition and increased adipokine production and plasma free fatty acid levels both contributing to insulin resistance and inflammation. Alternatively, it can initiate an inflammatory process either originating from the intestine or generated at the peripheral level via endotoxin leakage into the blood from the intestine, both leading secondarily to insulin resistance.

aEA4466, Département de Biologie Expérimentale, Métabolique et Clinique, France

bEA4065, Département Périnatalité, Microbiologie, Médicament, Faculté des Sciences Pharmaceutiques Paris Descartes, France

cClinical Chemistry, Cochin-Broca-Hotel Dieu, APHP, Paris, France

Correspondence to Dr Jean-Pascal De Bandt, EA4466, Département de Biologie Expérimentale, Métabolique et Clinique, 4 avenue de l'Observatoire, 75270 Paris cedex 06, France Tel: +33 1 53739953; fax: +33 1 53739952; e-mail:

© 2011 Lippincott Williams & Wilkins, Inc.